{"gene":"UBA1","run_date":"2026-06-10T10:51:56","timeline":{"discoveries":[{"year":2020,"finding":"Somatic mutations at p.Met41 in UBA1 result in loss of the canonical cytoplasmic isoform of UBA1 (UBA1b) and expression of a novel, catalytically impaired isoform initiated at p.Met67. Mutant peripheral-blood cells showed decreased ubiquitylation and activated innate immune pathways. Knockout of the cytoplasmic UBA1 isoform homologue in zebrafish caused systemic inflammation.","method":"Immunoblotting, flow cytometry, transcriptome and cytokine profiling, CRISPR-Cas9 zebrafish knockout","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (immunoblotting, flow cytometry, in vivo CRISPR model), independently replicated across subsequent studies","pmids":["33108101"],"is_preprint":false},{"year":2022,"finding":"The p.Met41Val variant supports less UBA1b (cytoplasmic isoform) translation than p.Met41Leu or p.Met41Thr, as shown by in vitro reporter assays. Residual UBA1b translation level is fundamental to VEXAS pathogenesis and prognosis. A second mutation (p.Gly40Ala) in cis rescued UBA1b translation levels reduced by p.Met41Leu.","method":"In vitro reporter translation assay, patient-derived cell analysis, multivariate survival analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct in vitro reporter assay with mutagenesis, replicated across multiple patient genotypes and patient-derived cells","pmids":["35793467"],"is_preprint":false},{"year":2024,"finding":"p.Met41 VEXAS mutations alter cytoplasmic isoform expression, whereas non-p.Met41 VEXAS mutations reduce catalytic activity of nuclear and cytoplasmic isoforms by diverse mechanisms including aberrant oxyester formation. Non-p.Met41 mutations most prominently impair transthioesterification (ubiquitin transfer to cytoplasmic E2 enzymes). SMA-causing UBA1 mutations instead render UBA1 thermolabile rather than blocking E2 charging.","method":"In vitro enzymatic assays (ubiquitin thioester formation, transthioesterification, oxyester detection), mutagenesis, patient-derived cell analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple in vitro biochemical assays with mutagenesis across diverse disease-causing variants, replicated in preprint (PMID 37873213)","pmids":["38360993","37873213"],"is_preprint":false},{"year":2012,"finding":"UBA1 is required for ubiquitin conjugate formation at DNA double-strand break sites. siRNA knockdown of UBA1 (but not UBA6) impaired formation of ubiquitin conjugates at DNA damage sites and prevented IR-induced foci (IRIF) by 53BP1 and BRCA1. Chemical inhibition of UBA1 prevented IRIF formation and severely impaired DSB repair. Upstream steps (H2AX phosphorylation, MDC1 recruitment) were unaffected.","method":"siRNA knockdown, chemical inhibition, immunofluorescence for IRIF, comet assay for DSB repair","journal":"Cell cycle (Georgetown, Tex.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic (siRNA) and pharmacological inhibition with multiple orthogonal readouts; negative result for UBA6 specificity controls","pmids":["22456334"],"is_preprint":false},{"year":2018,"finding":"TAK-243 preferentially binds UBA1 over related E1 enzymes UBA2, UBA3, and UBA6 in intact AML cells. Missense mutations in the adenylation domain of UBA1 confer resistance to TAK-243, identifying the adenylation domain as the inhibitor binding site.","method":"Activity-based protein profiling in intact cells, selection of drug-resistant cell populations with missense mutation identification","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct target engagement assay in cells, resistance mutations confirm on-target mechanism","pmids":["29884901"],"is_preprint":false},{"year":2017,"finding":"Crystal structure of S. pombe Uba1 in complex with Ubc15 reveals a distinct E2 binding mode that substantially alters the interaction network at the E1-E2 interface compared to previously solved E1-E2 structures. The intrinsically low E2 activity of Ubc15 results from an acidic residue at its N-terminal region. Phosphorylation of serine/threonine-rich N termini of other Ub E2s was demonstrated biochemically and in cells to serve as a negative regulatory mechanism of E2 activity.","method":"X-ray crystallography, structure-function mutagenesis, biochemical E2 charging assays, cell-based phosphorylation assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus functional mutagenesis and orthogonal biochemical and cell-based validation","pmids":["28162934"],"is_preprint":false},{"year":2023,"finding":"Auranofin binds to UBA1's ubiquitin fold domain and conjugates to Cys1039, enhancing UBA1 interactions with at least 20 different E2 ubiquitin-conjugating enzymes and facilitating ubiquitin charging to E2. This increases activities of seven representative E3s in vitro and promotes ubiquitination and degradation of misfolded ER proteins during ER-associated degradation and outer mitochondrial membrane-associated degradation.","method":"Biochemical binding assay, covalent modification mapping (Cys1039), in vitro E2 charging assay, E3 activity assay, cellular ERAD assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal in vitro assays plus cell-based validation, with identification of binding site by mutagenesis","pmids":["37558718"],"is_preprint":false},{"year":2018,"finding":"UBA1 is recruited to DNA by poly(ADP-ribose) (PAR), and this PAR-mediated association is necessary for ATR-dependent phosphorylation of RPA and CHK1 in response to DNA damage. UBA1 interacts directly with PAR via a solvent-accessible, positively charged patch conserved in Animalia but not Fungi.","method":"Human cell-free system, PAR interaction assay, direct UBA1-PAR binding assay, ATR signaling readout (RPA/CHK1 phosphorylation)","journal":"Life science alliance","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — reconstituted cell-free system, direct binding demonstrated, functional consequence (ATR signaling) measured, conservation analysis supports mechanism","pmids":["30456359"],"is_preprint":false},{"year":2016,"finding":"UBA1 levels are reduced in mouse and zebrafish SMA models and in patient iPSC-derived motor neurons. Systemic AAV9-mediated restoration of UBA1 in SMA mice ameliorated weight loss, increased survival and motor performance, and improved neuromuscular pathology, reversing widespread ubiquitin homeostasis perturbations.","method":"AAV9 gene therapy in SMA mice, zebrafish rescue experiments, iPSC motor neuron derivation, ubiquitin conjugate measurement","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo rescue in two model organisms with multiple functional readouts, replicated mechanistic link between SMN loss and UBA1 reduction","pmids":["27699224"],"is_preprint":false},{"year":2018,"finding":"Restoration of UBA1 was sufficient to correct sensory-motor connectivity defects in SMA mice. Aminoacyl-tRNA synthetase GARS was identified as a downstream target of UBA1, regulated by a non-canonical pathway independent of ubiquitylation. Dysregulation of UBA1/GARS disrupted sensory neuron fate, phenocopying GARS-dependent Charcot-Marie-Tooth defects.","method":"AAV9-UBA1 rescue in SMA mice, proteomics (GARS identification as UBA1 target), sensory-motor connectivity electrophysiology, genetic epistasis","journal":"Brain : a journal of neurology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo rescue, proteomics-based substrate identification, epistasis with GARS, multiple orthogonal functional readouts","pmids":["30239612"],"is_preprint":false},{"year":2013,"finding":"Uba1 (the E1 ubiquitin-activating enzyme) is required for an Atg7- and Atg3-independent autophagy pathway in Drosophila intestinal cells during programmed cell size reduction. Loss of Uba1 function blocks autophagy and cell shrinkage, revealing a role for ubiquitin activation in autophagy distinct from canonical Atg8 conjugation.","method":"Genetic loss-of-function in Drosophila, autophagy and cell size assays, epistasis with Atg7/Atg3/Atg8","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in Drosophila with clear functional readout, contrasted with Atg7/Atg3 null controls","pmids":["23873149"],"is_preprint":false},{"year":2007,"finding":"In Drosophila, weak Uba1 alleles protect cells from apoptosis while strong alleles cause apoptosis and cell cycle arrest with failure to degrade cyclins. Strong Uba1 mutant clones non-autonomously stimulate neighboring wild-type tissue to proliferate by failing to downregulate Notch signaling.","method":"Drosophila genetic mosaic analysis, clonal analysis, cyclin immunostaining, Notch pathway epistasis","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — Drosophila mosaic genetics with multiple alleles, mechanistic link to Notch signaling and cyclin degradation demonstrated","pmids":["18045837"],"is_preprint":false},{"year":2021,"finding":"Acetylation of ubiquitin at K11, K27, K33, K48, or K63 alters the turnover number for E2~Ub conjugate formation by the E1 enzyme Uba1, as shown by FRET-based kinetic assays. Acetylation at specific Ub lysines modulates catalytic efficiency of the UBA1-mediated E2 charging step.","method":"In vitro synthesis of acetylated ubiquitin variants, FRET-based kinetic E2 charging assay (CyPet-Ub/YPet-E2)","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with synthetic substrates and kinetic measurements, single lab but rigorous","pmids":["33848125"],"is_preprint":false},{"year":2023,"finding":"A novel UBA1 variant p.Gly477Ala leads to both decreased E1 ubiquitin thioester formation and decreased E2 enzyme charging, demonstrated by in vitro enzymatic assays, expanding the catalog of catalytic loss-of-function mechanisms in VEXAS.","method":"In vitro ubiquitin thioester formation assay, E2 charging assay","journal":"Arthritis & rheumatology (Hoboken, N.J.)","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro enzymatic assay, single lab, single variant","pmids":["36762418"],"is_preprint":false},{"year":2023,"finding":"In vitro enzymatic assay of a novel UBA1 variant p.Ser621Cys demonstrated a catalytic defect, supporting pathogenicity in VEXAS syndrome.","method":"In vitro enzymatic assay","journal":"JAMA","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — single in vitro assay, single variant, single lab","pmids":["36692560"],"is_preprint":false},{"year":2017,"finding":"Of three known XL-SMA missense variants in the adenylation domain (Exon 15) of UBA1, only one impairs ubiquitin-adenylating (adenylation) activity in vitro, while all three retain normal ubiquitin thioester formation and transthioesterification rates equal to wild-type.","method":"In vitro Uba1 adenylation assay, thioester formation assay, transthioesterification assay","journal":"F1000Research","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct in vitro enzymatic characterization of three variants, single lab, limited mechanistic follow-up","pmids":["29034082"],"is_preprint":false},{"year":2014,"finding":"A Met256Ile point mutation in Uba1 (tsTM3 cells) causes loss of nuclear UBA1 at non-permissive temperature, impairs ubiquitin system function in the nucleus, leads to accumulation of geminin and Cdt1 (DNA replication licensing factors), and causes S-to-G2 cell cycle arrest. Nuclear localization of UBA1 is required to rescue these defects.","method":"Temperature-sensitive CHO mutant complementation, GFP-Uba1 localization, fluorescent cell cycle indicator, Western blot for geminin/Cdt1","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — temperature-sensitive mutant with complementation, localization and functional readouts, single lab","pmids":["24805847"],"is_preprint":false},{"year":2012,"finding":"Cys278 of UBA1 affects ubiquitin charging through conformational changes rather than direct participation at the UBA1-ubiquitin interface; UBA1(C278S) mutant forms a thioester on Cys632 (canonical catalytic cysteine) but ubiquitin conjugates persist longer compared to wild-type, indicating impaired downstream transfer.","method":"Site-directed mutagenesis (C278S, C632S), ubiquitin thioester assay, transfection of HEK293T and CMT93 cells","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1-2 / Weak — mutagenesis with in vitro/cell-based assay, single lab, single study","pmids":["23022194"],"is_preprint":false},{"year":2011,"finding":"UBA1 localizes to the acrosomal caps of spermatids and is enzymatically active in isolated sperm acrosomes (confirmed by thiol ester assay with biotinylated ubiquitin). Pharmacological inhibition of UBA1 with PYR-41 during sperm capacitation alters outer acrosomal membrane remodeling, impairs capacitation-induced protein modifications, and significantly reduces in vitro fertilization rates.","method":"Western blotting, immunofluorescence, thiol ester assay on isolated acrosomes, flow cytometry (FITC-PNA), in vitro fertilization with PYR-41 inhibitor","journal":"International journal of andrology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — enzymatic activity confirmed in isolated organelles plus pharmacological inhibition with functional readout, single lab","pmids":["21950462"],"is_preprint":false},{"year":2008,"finding":"Temperature-sensitive mutation in C. elegans uba-1 (the sole E1 enzyme) substantially reduces ubiquitin conjugate levels and causes meiotic progression delays in early embryos, synthetic lethality with anaphase-promoting complex (APC/C) alleles, and defects in sperm fertility, body size control, and sex-specific development.","method":"C. elegans temperature-sensitive genetics, ubiquitin conjugate immunoblot, genetic epistasis with APC/C mutants","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple developmental phenotypes with epistasis to APC/C, biochemical confirmation of reduced conjugates, replicated across developmental stages","pmids":["18636104"],"is_preprint":false},{"year":2025,"finding":"UBA1M41V-mutated monocytes exhibit TNF-α-induced cell death characterized by RIPK1 phosphorylation and MLKL/caspase-8-mediated death, associated with defective NF-κB transcriptional induction and reduced cFLIP(L). UBA1-mutated macrophages display an inflammatory transcriptional profile with increased chemokine secretion and defective efferocytosis due to lysosomal dysfunction.","method":"CRISPR-engineered THP-1 monocytic cell model (UBA1 M41V), ex vivo patient samples, RIPK1 phosphorylation assay, MLKL/caspase-8 activation assays, NF-κB reporter, efferocytosis assay","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — engineered human cell model plus patient-derived samples, multiple mechanistic readouts, preprint not yet peer reviewed","pmids":["bio_10.1101_2025.10.06.680650"],"is_preprint":true},{"year":2025,"finding":"Neutrophil-specific Uba1 depletion (to ~30% residual Uba1) in mice induces VEXAS-like autoinflammatory symptoms including increased neutrophil counts, elevated proinflammatory cytokines (IL-1β, IL-6, TNFα), myeloid vacuoles, and dermatitis. Loss of Uba1 in HSCs, B cells, T cells, or megakaryocytes does not produce autoinflammatory disease, identifying neutrophils as a key pathogenic cell type.","method":"Nine Cre/flox conditional knockout mouse models, flow cytometry, cytokine measurement, histology","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic comparison of nine cell-type-specific CKO models, clear epistasis, in vivo functional readout, published peer-reviewed","pmids":["40906528"],"is_preprint":false},{"year":2025,"finding":"UBA1M41V mutant cells exhibit acquired dependency on UBA6 (a paralogous E1 enzyme) that compensates for UBA1 dysfunction. TAK-243 preferentially inhibits UBA6 activity over UBA1 at relevant concentrations. Genetic or pharmacological inhibition of UBA6 selectively impairs growth and colony formation of UBA1M41V cells while sparing wild-type cells.","method":"CRISPR-engineered THP1 UBA1M41V model, proteomic analysis, shRNA knockdown, phytic acid (UBA6-specific inhibitor), competition colony formation assay","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — engineered human cell model, multiple genetic and pharmacological approaches, single lab","pmids":["40588566"],"is_preprint":false},{"year":2025,"finding":"UBA1 directly interacts with ATG5 and promotes its ubiquitination and proteasomal degradation, leading to autophagy suppression. Cardiomyocyte-specific UBA1 knockdown protects against TAC-induced hypertrophy by preserving ATG5-mediated autophagy; ATG5 deletion abrogates this protection.","method":"Co-immunoprecipitation, ubiquitination assay, rAAV9-mediated knockdown/overexpression in mice, TAC model, ATG5 epistasis by deletion","journal":"Cell communication and signaling : CCS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus in vivo genetic epistasis, multiple readouts, single lab, newly published","pmids":["41765888"],"is_preprint":false},{"year":2025,"finding":"UBA1 interacts with BMAL1 and increases its ubiquitination and proteasomal degradation in macrophages, reducing REV-ERBα transcriptional activity and increasing proinflammatory cytokine production, thereby exacerbating sepsis-associated liver dysfunction.","method":"Macrophage-specific UBA1 knockout mice, co-immunoprecipitation, ubiquitination assay, CLP sepsis model, liver function and cytokine measurements","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, in vivo KO model, mechanistic pathway identification, single lab","pmids":["41205381"],"is_preprint":false},{"year":2021,"finding":"In VEXAS, UBA1-mutated hematopoietic stem and progenitor cells (HSPCs) are biased toward myeloid (granulocytic) differentiation and away from lymphoid differentiation. Activation of interferon and TNF-α inflammatory pathways occurs in primitive hematopoietic cells and particularly in the myeloid lineage, with inflammation intrinsic to UBA1-mutated HSCs.","method":"Single-cell transcriptome sequencing of bone marrow mononuclear cells and HSPCs from VEXAS patients","journal":"Cell reports. Medicine","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single-cell transcriptomics across multiple patients, but transcriptomic rather than direct mechanistic experiment","pmids":["37586319"],"is_preprint":false},{"year":2023,"finding":"AZGP1P2 binds to UBA1 and RBM15; UBA1 promotes ubiquitin-dependent degradation of RBM15 via ubiquitination. This was shown by RNA pull-down with mass spectrometry, co-immunoprecipitation, and RNA immunoprecipitation assays.","method":"RNA pull-down/mass spectrometry, co-immunoprecipitation, RNA immunoprecipitation, xenograft mouse model","journal":"Research (Washington, D.C.)","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP plus functional degradation readout, multiple methods, single lab","pmids":["37854295"],"is_preprint":false},{"year":2023,"finding":"UBA1 inhibition by TAK-243 impairs homologous recombination (HR) DNA repair and increases PARylation, sensitizing HR-proficient ovarian cancer cells to PARP inhibitors. A genome-wide CRISPR knockout screen identified UBA1 depletion as conferring sensitivity to PARPi.","method":"Genome-wide CRISPR KO screen, siRNA/pharmacological UBA1 inhibition, HR repair assay, PARylation assay, patient-derived xenograft in vivo combination study","journal":"Cell reports. Medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR screen discovery confirmed with orthogonal genetic and pharmacological methods, mechanistic HR assay, and in vivo validation","pmids":["39626673"],"is_preprint":false},{"year":2025,"finding":"A modular Uba1-nanobody (VHH05) fusion enzyme (Uba1-VHH05), in which the ubiquitin-fold domain (UFD) is replaced by a nanobody, selectively transfers ubiquitin to E2 enzymes fused to the cognate epitope tag, demonstrating that the UFD of Uba1 is the domain responsible for E2 selection and ubiquitin transfer specificity.","method":"Domain-swap protein engineering, in vitro ubiquitin transfer assay, Ub-Dha activity-based probe, polyubiquitin chain formation reconstitution","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct in vitro reconstitution with engineered enzyme, single lab, single study","pmids":["41203132"],"is_preprint":false},{"year":2025,"finding":"SF3B1K700E mutation causes mis-splicing of UBA1 transcripts in hematopoietic cells, introducing protein instability and decreasing total UBA1 protein levels, thereby rendering SF3B1-mutated cells selectively vulnerable to UBA1 inhibitor TAK-243.","method":"Isogenic SF3B1K700E/WT iPSC lines differentiated into hematopoietic cells, full-length RNA sequencing, Western blot, TAK-243 colony-forming assay on primary CD34+ MDS cells","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 / Strong — isogenic cell model, confirmed in primary patient CD34+ cells and MDS cohort RNA-seq, multiple orthogonal methods","pmids":["40858805"],"is_preprint":false}],"current_model":"UBA1 is the primary E1 ubiquitin-activating enzyme that initiates ubiquitin conjugation by adenylating ubiquitin and forming a high-energy thioester at its catalytic cysteine (Cys632), then transfers ubiquitin to tens of E2 conjugating enzymes via its C-terminal ubiquitin-fold domain; it exists as distinct nuclear and cytoplasmic isoforms (the cytoplasmic isoform, UBA1b, is translated from Met41), functions at DNA damage sites via poly(ADP-ribose)-mediated recruitment to support ATR signaling, regulates autophagy and cell cycle progression, and controls specific substrate ubiquitination events including BMAL1 and ATG5 degradation; somatic loss-of-function mutations at Met41 specifically abrogate cytoplasmic UBA1b expression, reducing E2 charging and causing the VEXAS inflammatory-hematologic syndrome, while other disease-causing mutations impair transthioesterification or render the enzyme thermolabile through distinct mechanisms."},"narrative":{"mechanistic_narrative":"UBA1 is the principal E1 ubiquitin-activating enzyme that initiates the ubiquitin conjugation cascade by adenylating ubiquitin, forming a high-energy thioester at its catalytic cysteine (Cys632), and charging ubiquitin onto downstream E2 conjugating enzymes [PMID:38360993, PMID:37873213, PMID:23022194]. Its C-terminal ubiquitin-fold domain (UFD) is the determinant of E2 selection and transfer specificity: replacing the UFD with a nanobody redirects ubiquitin transfer exclusively to epitope-tagged E2s [PMID:41203132]. Charging activity is tunable through multiple inputs — acetylation of distinct ubiquitin lysines alters E2~Ub turnover [PMID:33848125], covalent modification of the UFD at Cys1039 by auranofin enhances E2 engagement across more than twenty E2 enzymes [PMID:37558718], and E2 N-terminal phosphorylation acts as a negative regulator at the E1-E2 interface [PMID:28162934]. UBA1 exists as nuclear and cytoplasmic isoforms; the cytoplasmic isoform (UBA1b) is translated from Met41, and its nuclear pool is required to maintain ubiquitin-dependent turnover of replication-licensing factors and orderly S-to-G2 progression [PMID:33108101, PMID:24805847]. The enzyme acts at DNA double-strand breaks, where poly(ADP-ribose) recruits UBA1 to support ubiquitin-conjugate formation, 53BP1/BRCA1 focus assembly, and ATR-dependent phosphorylation of RPA and CHK1 [PMID:22456334, PMID:30456359]. Beyond bulk conjugation, UBA1 controls specific substrate-degradation events, directly ubiquitinating ATG5 to suppress autophagy [PMID:41765888] and BMAL1 to dampen REV-ERBα activity and amplify inflammatory cytokine output [PMID:41205381], and it participates in a non-canonical autophagy pathway and APC/C-coupled cyclin degradation conserved across model organisms [PMID:23873149, PMID:18045837, PMID:18636104]. Somatic Met41 mutations selectively abrogate UBA1b, reducing E2 charging and causing the inflammatory-hematologic VEXAS syndrome, whereas germline mutations cause spinal muscular atrophy by rendering the enzyme thermolabile; non-Met41 disease variants instead impair transthioesterification or catalytic activity through distinct mechanisms including aberrant oxyester formation [PMID:33108101, PMID:35793467, PMID:38360993, PMID:37873213, PMID:27699224]. UBA1 inhibition or loss is being leveraged therapeutically, with TAK-243-mediated E1 blockade impairing homologous recombination and sensitizing cancers to PARP inhibition [PMID:39626673].","teleology":[{"year":2007,"claim":"Established that E1 ubiquitin activation gates cell-cycle progression and tissue homeostasis, not merely bulk protein turnover, by linking Uba1 loss to failed cyclin degradation and aberrant Notch signaling.","evidence":"Drosophila mosaic clonal genetics with multiple alleles, cyclin immunostaining and Notch epistasis","pmids":["18045837"],"confidence":"High","gaps":["Does not identify which E3/E2 routes the cyclin and Notch ubiquitination","Phenotypes are organismal, leaving the direct substrate set undefined"]},{"year":2008,"claim":"Showed the sole organismal E1 is required across meiosis, fertility, and development and operates upstream of the APC/C, defining the breadth of processes dependent on ubiquitin activation.","evidence":"C. elegans temperature-sensitive uba-1 genetics, ubiquitin-conjugate immunoblot, epistasis with APC/C mutants","pmids":["18636104"],"confidence":"High","gaps":["Does not resolve substrate-level mechanisms for individual phenotypes","Genetic, not biochemical, link to APC/C"]},{"year":2012,"claim":"Identified UBA1 as the specific E1 that drives ubiquitin-conjugate formation at DNA double-strand breaks, placing ubiquitin activation downstream of damage sensing but upstream of repair-factor recruitment.","evidence":"siRNA knockdown and chemical inhibition with IRIF imaging and comet repair assay, UBA6 negative controls","pmids":["22456334"],"confidence":"High","gaps":["Does not identify the recruiting signal or relevant E2/E3 at breaks","Does not define which repair-pathway substrates require UBA1"]},{"year":2012,"claim":"Refined the catalytic mechanism by showing Cys278 influences ubiquitin charging through conformational change rather than direct chemistry, distinguishing the canonical catalytic Cys632 from allosteric cysteines.","evidence":"Site-directed mutagenesis (C278S, C632S), thioester assays in HEK293T and CMT93 cells","pmids":["23022194"],"confidence":"Medium","gaps":["Single lab, no structural confirmation of the proposed conformational change","Downstream transfer defect inferred from conjugate persistence rather than direct kinetics"]},{"year":2013,"claim":"Revealed a ubiquitin-activation requirement for a non-canonical autophagy pathway independent of the Atg7/Atg3 conjugation machinery, broadening UBA1's role in degradative cell biology.","evidence":"Drosophila loss-of-function with autophagy/cell-size assays and Atg7/Atg3/Atg8 epistasis","pmids":["23873149"],"confidence":"High","gaps":["Does not define the ubiquitin substrates that drive this autophagy route","Mechanism of Atg-independence unresolved"]},{"year":2014,"claim":"Demonstrated that nuclear UBA1 localization is specifically required to maintain ubiquitin-dependent turnover of replication-licensing factors and prevent S/G2 arrest, separating nuclear from cytoplasmic enzyme function.","evidence":"Temperature-sensitive CHO mutant (Met256Ile) complementation, GFP-Uba1 imaging, geminin/Cdt1 immunoblot","pmids":["24805847"],"confidence":"Medium","gaps":["Single lab, single mutant","Mechanism of UBA1 nuclear import not addressed"]},{"year":2016,"claim":"Connected UBA1 reduction causally to spinal muscular atrophy pathology by showing AAV9-delivered UBA1 restores survival, motor function, and ubiquitin homeostasis in vivo.","evidence":"AAV9 gene therapy in SMA mice, zebrafish rescue, iPSC motor neurons, ubiquitin-conjugate measurement","pmids":["27699224"],"confidence":"High","gaps":["Does not identify the disease-relevant substrates downstream of UBA1 loss","Does not explain how SMN loss reduces UBA1"]},{"year":2017,"claim":"Provided structural and biochemical definition of the E1-E2 interface and showed E2 N-terminal phosphorylation negatively regulates charging, identifying a post-translational control layer on UBA1 output.","evidence":"X-ray crystallography of S. pombe Uba1-Ubc15, structure-function mutagenesis, biochemical and cell-based phosphorylation assays","pmids":["28162934"],"confidence":"High","gaps":["Structure from fission yeast ortholog","Generality of phospho-regulation across human E2s not exhaustively mapped"]},{"year":2017,"claim":"Showed XL-SMA adenylation-domain variants mostly retain thioester and transthioesterification activity, indicating SMA pathogenicity is not simply a charging block and pointing toward subtler defects.","evidence":"In vitro adenylation, thioester, and transthioesterification assays on three variants","pmids":["29034082"],"confidence":"Medium","gaps":["Single lab, three variants only","Does not establish the in vivo defect for the two variants with normal in vitro activity"]},{"year":2018,"claim":"Identified poly(ADP-ribose) as the recruitment signal that brings UBA1 to damaged DNA and showed this association is required for ATR-dependent RPA/CHK1 phosphorylation, defining a mechanism for UBA1 action at breaks.","evidence":"Human cell-free system, direct UBA1-PAR binding assay, ATR signaling readouts, conservation analysis","pmids":["30456359"],"confidence":"High","gaps":["Does not identify ubiquitination substrates feeding ATR activation","PAR-binding patch mapped by conservation rather than structure"]},{"year":2018,"claim":"Linked UBA1 to neuronal connectivity and identified GARS as a downstream target regulated non-canonically and independent of ubiquitylation, expanding UBA1 function beyond conjugation chemistry.","evidence":"AAV9-UBA1 rescue in SMA mice, proteomics, sensory-motor electrophysiology, GARS epistasis","pmids":["30239612"],"confidence":"High","gaps":["Molecular nature of the non-canonical UBA1-GARS regulation unresolved","Generality beyond sensory neurons unknown"]},{"year":2018,"claim":"Validated UBA1 as the cellular target of TAK-243 and mapped the adenylation domain as the inhibitor binding site through resistance mutations, enabling pharmacological dissection and therapeutic targeting.","evidence":"Activity-based protein profiling in intact AML cells, selection of drug-resistant missense mutations","pmids":["29884901"],"confidence":"High","gaps":["Selectivity over UBA6 later shown to be concentration-dependent","Does not define the substrate-level consequences of inhibition"]},{"year":2020,"claim":"Defined the molecular basis of VEXAS by showing somatic Met41 mutations ablate cytoplasmic UBA1b, generate an impaired Met67-initiated isoform, reduce ubiquitylation, and trigger innate immune activation.","evidence":"Immunoblotting, flow cytometry, transcriptome/cytokine profiling, CRISPR zebrafish knockout","pmids":["33108101"],"confidence":"High","gaps":["Does not establish which inflammatory substrates accumulate","Cell-type origin of disease not pinpointed"]},{"year":2021,"claim":"Quantified ubiquitin acetylation as a regulator of UBA1 catalytic efficiency, showing site-specific lysine acetylation tunes E2~Ub turnover and adds a substrate-side control on the cascade.","evidence":"Synthetic acetylated ubiquitin variants and FRET-based kinetic E2-charging assay","pmids":["33848125"],"confidence":"High","gaps":["In vitro only; physiological acetylation stoichiometry unknown","Single lab"]},{"year":2021,"claim":"Localized VEXAS inflammation to the hematopoietic stem cell compartment, showing UBA1-mutant HSPCs are myeloid-biased and intrinsically activate interferon/TNF programs.","evidence":"Single-cell transcriptome sequencing of patient bone marrow and HSPCs","pmids":["37586319"],"confidence":"Medium","gaps":["Transcriptomic correlation rather than direct mechanism","Does not identify the molecular trigger of lineage bias"]},{"year":2022,"claim":"Established that residual UBA1b translation level dictates VEXAS severity, with Met41 variants ranked by translational output and a cis Gly40Ala mutation able to rescue UBA1b.","evidence":"In vitro reporter translation assay, patient-derived cells, multivariate survival analysis","pmids":["35793467"],"confidence":"High","gaps":["Does not connect translation level to specific downstream substrate defects","Reporter-based quantification of translation"]},{"year":2023,"claim":"Showed UBA1 inhibition impairs homologous recombination and elevates PARylation, providing a mechanistic rationale for combining E1 blockade with PARP inhibition in cancer.","evidence":"Genome-wide CRISPR screen, genetic/pharmacological UBA1 inhibition, HR and PARylation assays, patient-derived xenograft","pmids":["39626673"],"confidence":"High","gaps":["HR substrates requiring UBA1 not individually identified","Relationship to the PAR-recruitment mechanism at breaks not directly tested"]},{"year":2023,"claim":"Mapped a regulatory small molecule (auranofin) to the UFD at Cys1039 and showed UFD modification enhances E2 engagement and downstream E3 and ERAD/OMMAD activity, reinforcing the UFD as the E2-handoff module.","evidence":"Biochemical binding, Cys1039 mapping, E2-charging and E3-activity assays, cellular ERAD assay","pmids":["37558718"],"confidence":"High","gaps":["Physiological ligand of this UFD site unknown","Whether endogenous modification regulates UBA1 in cells untested"]},{"year":2024,"claim":"Resolved the distinct biochemical lesions across UBA1 disease variants, showing Met41 mutations alter isoform expression while non-Met41 mutations impair catalysis (including aberrant oxyester formation) and SMA mutations confer thermolability.","evidence":"In vitro thioester, transthioesterification, and oxyester assays with mutagenesis and patient cells","pmids":["38360993","37873213"],"confidence":"High","gaps":["Does not link each biochemical defect to a clinical phenotype quantitatively","In vitro assays may not capture cellular compensation"]},{"year":2025,"claim":"Identified the UFD as the structural determinant of E2 selection by demonstrating that a UFD-to-nanobody swap redirects ubiquitin transfer to tagged E2 partners.","evidence":"Domain-swap protein engineering and in vitro ubiquitin-transfer and polyubiquitin reconstitution","pmids":["41203132"],"confidence":"Medium","gaps":["Engineered system; native UFD-E2 contact map not solved here","Single lab/study"]},{"year":2025,"claim":"Pinpointed neutrophils as the pathogenic cell type in VEXAS-like disease, showing partial Uba1 depletion in neutrophils—but not HSCs, lymphocytes, or megakaryocytes—reproduces autoinflammation.","evidence":"Nine Cre/flox conditional knockout mouse models with cytokine, flow, and histology readouts","pmids":["40906528"],"confidence":"High","gaps":["Reconciliation with HSC-intrinsic inflammation reports unresolved","Molecular trigger within neutrophils not defined"]},{"year":2025,"claim":"Defined cell-death and inflammatory consequences of UBA1 dysfunction, linking Met41 mutation to TNF-driven RIPK1/MLKL/caspase-8 death, defective NF-κB induction, and impaired macrophage efferocytosis.","evidence":"CRISPR THP-1 UBA1 M41V model and patient samples, RIPK1/MLKL/caspase-8 and NF-κB and efferocytosis assays (preprint)","pmids":["bio_10.1101_2025.10.06.680650"],"confidence":"Medium","gaps":["Not yet peer reviewed","Direct substrate causing NF-κB defect not identified"]},{"year":2025,"claim":"Revealed an acquired UBA6 dependency in UBA1-mutant cells, showing the paralogous E1 compensates and is selectively targetable, refining the pharmacology of E1 inhibition.","evidence":"CRISPR THP-1 UBA1 M41V model, proteomics, shRNA, phytic acid (UBA6 inhibitor), competition colony assays","pmids":["40588566"],"confidence":"Medium","gaps":["Single lab, engineered cell model","Mechanism of UBA6 compensation not detailed"]},{"year":2025,"claim":"Extended UBA1's substrate repertoire to specific degradation targets driving disease, showing direct ubiquitination and proteasomal degradation of ATG5 (suppressing protective autophagy in cardiac hypertrophy), BMAL1 (amplifying inflammation in sepsis), and RBM15 in cancer.","evidence":"Co-IP, ubiquitination assays, in vivo conditional knockdown/knockout with epistasis (ATG5/BMAL1/RBM15)","pmids":["41765888","41205381","37854295"],"confidence":"Medium","gaps":["Each substrate shown in a single lab/context","The E2/E3 partners mediating these specific events not identified"]},{"year":2025,"claim":"Connected splicing-factor mutations to UBA1 vulnerability, showing SF3B1K700E mis-splices UBA1 and lowers its level, sensitizing mutant hematopoietic cells to TAK-243.","evidence":"Isogenic SF3B1 iPSC-derived hematopoietic cells, full-length RNA-seq, Western blot, TAK-243 colony assay on primary CD34+ MDS cells","pmids":["40858805"],"confidence":"High","gaps":["Does not establish therapeutic window in patients","Mechanism of selective vulnerability beyond UBA1 reduction not fully resolved"]},{"year":null,"claim":"It remains unresolved which specific E2/E3 routes and substrate sets mediate UBA1's distinct functions at DNA breaks, in autophagy/cell cycle, and in inflammatory signaling, and how reduced cytoplasmic charging is mechanistically converted into the cell-type-specific inflammatory program of VEXAS.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified mechanism linking UBA1b loss to neutrophil-intrinsic inflammation","Substrate-level changes upon partial E1 loss largely uncharacterized","Reconciliation of HSC-intrinsic versus neutrophil-specific disease models pending"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[2,17,23,24,26]},{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[2,5,28]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[2,4,15]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[2,17]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[16]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,16]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[2,6]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[3,7,27]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[11,16,19]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[10,23]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,20,21,24,25]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,2,8]}],"complexes":[],"partners":["UBA6","ATG5","BMAL1","RBM15","GARS","AZGP1P2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P22314","full_name":"Ubiquitin-like modifier-activating enzyme 1","aliases":["Protein A1S9","Ubiquitin-activating enzyme E1"],"length_aa":1058,"mass_kda":117.8,"function":"Catalyzes the first step in ubiquitin conjugation to mark cellular proteins for degradation through the ubiquitin-proteasome system (PubMed:1447181, PubMed:1606621, PubMed:33108101). Activates ubiquitin by first adenylating its C-terminal glycine residue with ATP, and thereafter linking this residue to the side chain of a cysteine residue in E1, yielding a ubiquitin-E1 thioester and free AMP (PubMed:1447181). Essential for the formation of radiation-induced foci, timely DNA repair and for response to replication stress. Promotes the recruitment of TP53BP1 and BRCA1 at DNA damage sites (PubMed:22456334)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P22314/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/UBA1","classification":"Common Essential","n_dependent_lines":1207,"n_total_lines":1208,"dependency_fraction":0.9991721854304636},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000130985","cell_line_id":"CID001743","localizations":[{"compartment":"nucleoplasm","grade":3},{"compartment":"cytoplasmic","grade":2}],"interactors":[{"gene":"FRA10AC1","stoichiometry":0.2},{"gene":"DENND4A","stoichiometry":0.2},{"gene":"UBE2L3","stoichiometry":0.2},{"gene":"RPS27A","stoichiometry":0.2},{"gene":"UBE2N","stoichiometry":0.2},{"gene":"TUBGCP4","stoichiometry":0.2},{"gene":"UNNAMED","stoichiometry":0.2},{"gene":"TUBGCP3","stoichiometry":0.2},{"gene":"NEDD1","stoichiometry":0.2},{"gene":"TUBGCP6","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001743","total_profiled":1310},"omim":[{"mim_id":"619756","title":"UBIQUITIN-CONJUGATING ENZYME E2 J2; UBE2J2","url":"https://www.omim.org/entry/619756"},{"mim_id":"616319","title":"RING FINGER PROTEIN 138; RNF138","url":"https://www.omim.org/entry/616319"},{"mim_id":"616014","title":"RING FINGER PROTEIN 25; RNF25","url":"https://www.omim.org/entry/616014"},{"mim_id":"615380","title":"APOPTOSIS-RESISTANT E3 UBIQUITIN PROTEIN LIGASE 1; AREL1","url":"https://www.omim.org/entry/615380"},{"mim_id":"615211","title":"UBIQUITIN-LIKE PROTEIN CONTAINING PHD AND RING FINGER DOMAINS 2, E3 UBIQUITIN PROTEIN LIGASE; UHRF2","url":"https://www.omim.org/entry/615211"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/UBA1"},"hgnc":{"alias_symbol":["UBE1X","POC20","CFAP124"],"prev_symbol":["A1S9T","GXP1","UBE1"]},"alphafold":{"accession":"P22314","domains":[{"cath_id":"2.40.30.180","chopping":"217-295","consensus_level":"high","plddt":93.5399,"start":217,"end":295},{"cath_id":"1.10.10.2660","chopping":"639-733_740-874","consensus_level":"high","plddt":92.3829,"start":639,"end":874},{"cath_id":"3.10.290.60","chopping":"943-1055","consensus_level":"high","plddt":93.1835,"start":943,"end":1055}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P22314","model_url":"https://alphafold.ebi.ac.uk/files/AF-P22314-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P22314-F1-predicted_aligned_error_v6.png","plddt_mean":92.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=UBA1","jax_strain_url":"https://www.jax.org/strain/search?query=UBA1"},"sequence":{"accession":"P22314","fasta_url":"https://rest.uniprot.org/uniprotkb/P22314.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P22314/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P22314"}},"corpus_meta":[{"pmid":"33108101","id":"PMC_33108101","title":"Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.","date":"2020","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33108101","citation_count":925,"is_preprint":false},{"pmid":"34427584","id":"PMC_34427584","title":"Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1.","date":"2021","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/34427584","citation_count":197,"is_preprint":false},{"pmid":"36692560","id":"PMC_36692560","title":"Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population.","date":"2023","source":"JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/36692560","citation_count":190,"is_preprint":false},{"pmid":"33779074","id":"PMC_33779074","title":"Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS.","date":"2021","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/33779074","citation_count":171,"is_preprint":false},{"pmid":"34048852","id":"PMC_34048852","title":"Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS.","date":"2021","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34048852","citation_count":160,"is_preprint":false},{"pmid":"23873149","id":"PMC_23873149","title":"Uba1 functions in Atg7- and Atg3-independent autophagy.","date":"2013","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23873149","citation_count":156,"is_preprint":false},{"pmid":"35793467","id":"PMC_35793467","title":"Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/35793467","citation_count":147,"is_preprint":false},{"pmid":"26432019","id":"PMC_26432019","title":"UBA1: At the Crossroads of Ubiquitin Homeostasis and Neurodegeneration.","date":"2015","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26432019","citation_count":118,"is_preprint":false},{"pmid":"33789873","id":"PMC_33789873","title":"Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis.","date":"2021","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/33789873","citation_count":109,"is_preprint":false},{"pmid":"34495287","id":"PMC_34495287","title":"UBA1 Variations in Neutrophilic Dermatosis Skin Lesions of Patients With VEXAS Syndrome.","date":"2021","source":"JAMA dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/34495287","citation_count":93,"is_preprint":false},{"pmid":"22456334","id":"PMC_22456334","title":"Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage.","date":"2012","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/22456334","citation_count":89,"is_preprint":false},{"pmid":"29884901","id":"PMC_29884901","title":"Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia.","date":"2018","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/29884901","citation_count":76,"is_preprint":false},{"pmid":"27699224","id":"PMC_27699224","title":"Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy.","date":"2016","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/27699224","citation_count":73,"is_preprint":false},{"pmid":"18636104","id":"PMC_18636104","title":"E1 ubiquitin-activating enzyme UBA-1 plays multiple roles throughout C. elegans development.","date":"2008","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18636104","citation_count":65,"is_preprint":false},{"pmid":"12024044","id":"PMC_12024044","title":"UBA1 and UBA2, two proteins that interact with UBP1, a multifunctional effector of pre-mRNA maturation in plants.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12024044","citation_count":62,"is_preprint":false},{"pmid":"37666646","id":"PMC_37666646","title":"Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism.","date":"2023","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/37666646","citation_count":60,"is_preprint":false},{"pmid":"18045837","id":"PMC_18045837","title":"The E1 ubiquitin-activating enzyme Uba1 in Drosophila controls apoptosis autonomously and tissue growth non-autonomously.","date":"2007","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/18045837","citation_count":58,"is_preprint":false},{"pmid":"36823397","id":"PMC_36823397","title":"Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies.","date":"2023","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/36823397","citation_count":54,"is_preprint":false},{"pmid":"37586319","id":"PMC_37586319","title":"Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS.","date":"2023","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37586319","citation_count":53,"is_preprint":false},{"pmid":"8948595","id":"PMC_8948595","title":"Transcriptional analysis of the candidate spermatogenesis gene Ube1y and of the closely related Ube1x shows that they are coexpressed in spermatogonia and spermatids but are repressed in pachytene spermatocytes.","date":"1996","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/8948595","citation_count":53,"is_preprint":false},{"pmid":"34802541","id":"PMC_34802541","title":"Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome.","date":"2021","source":"Seminars in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/34802541","citation_count":51,"is_preprint":false},{"pmid":"36762418","id":"PMC_36762418","title":"Novel Somatic UBA1 Variant in a Patient With VEXAS Syndrome.","date":"2023","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/36762418","citation_count":48,"is_preprint":false},{"pmid":"28162934","id":"PMC_28162934","title":"S. pombe Uba1-Ubc15 Structure Reveals a Novel Regulatory Mechanism of Ubiquitin E2 Activity.","date":"2017","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/28162934","citation_count":46,"is_preprint":false},{"pmid":"38687605","id":"PMC_38687605","title":"Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.","date":"2024","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/38687605","citation_count":44,"is_preprint":false},{"pmid":"37854295","id":"PMC_37854295","title":"AZGP1P2/UBA1/RBM15 Cascade Mediates the Fate Determinations of Prostate Cancer Stem Cells and Promotes Therapeutic Effect of Docetaxel in Castration-Resistant Prostate Cancer via TPM1 m6A Modification.","date":"2023","source":"Research (Washington, D.C.)","url":"https://pubmed.ncbi.nlm.nih.gov/37854295","citation_count":44,"is_preprint":false},{"pmid":"23518311","id":"PMC_23518311","title":"Clinical and neuropathological features of X-linked spinal muscular atrophy (SMAX2) associated with a novel mutation in the UBA1 gene.","date":"2013","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/23518311","citation_count":44,"is_preprint":false},{"pmid":"38108611","id":"PMC_38108611","title":"Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.","date":"2023","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/38108611","citation_count":41,"is_preprint":false},{"pmid":"35165102","id":"PMC_35165102","title":"Targeting the Ubiquitin-Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer.","date":"2022","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/35165102","citation_count":41,"is_preprint":false},{"pmid":"30239612","id":"PMC_30239612","title":"UBA1/GARS-dependent pathways drive sensory-motor connectivity defects in spinal muscular atrophy.","date":"2018","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30239612","citation_count":37,"is_preprint":false},{"pmid":"38360993","id":"PMC_38360993","title":"Shared and distinct mechanisms of UBA1 inactivation across different diseases.","date":"2024","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/38360993","citation_count":34,"is_preprint":false},{"pmid":"37606963","id":"PMC_37606963","title":"Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome.","date":"2024","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/37606963","citation_count":33,"is_preprint":false},{"pmid":"21950462","id":"PMC_21950462","title":"Ubiquitin-activating enzyme (UBA1) is required for sperm capacitation, acrosomal exocytosis and sperm-egg coat penetration during porcine fertilization.","date":"2011","source":"International journal of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/21950462","citation_count":33,"is_preprint":false},{"pmid":"34480172","id":"PMC_34480172","title":"UBA1 and DNMT3A mutations in VEXAS syndrome. A case report and literature review.","date":"2022","source":"Modern rheumatology case reports","url":"https://pubmed.ncbi.nlm.nih.gov/34480172","citation_count":31,"is_preprint":false},{"pmid":"32315770","id":"PMC_32315770","title":"The pivotal role of ubiquitin-activating enzyme E1 (UBA1) in neuronal health and neurodegeneration.","date":"2020","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32315770","citation_count":30,"is_preprint":false},{"pmid":"35347123","id":"PMC_35347123","title":"GRP78 blockade overcomes intrinsic resistance to UBA1 inhibitor TAK-243 in glioblastoma.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35347123","citation_count":21,"is_preprint":false},{"pmid":"37558718","id":"PMC_37558718","title":"Auranofin targets UBA1 and enhances UBA1 activity by facilitating ubiquitin trans-thioesterification to E2 ubiquitin-conjugating enzymes.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37558718","citation_count":20,"is_preprint":false},{"pmid":"34301924","id":"PMC_34301924","title":"GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell death.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34301924","citation_count":20,"is_preprint":false},{"pmid":"35292885","id":"PMC_35292885","title":"Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants.","date":"2022","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/35292885","citation_count":19,"is_preprint":false},{"pmid":"33848125","id":"PMC_33848125","title":"Acetylated Ubiquitin Modulates the Catalytic Activity of the E1 Enzyme Uba1.","date":"2021","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33848125","citation_count":19,"is_preprint":false},{"pmid":"29034082","id":"PMC_29034082","title":"Functional characterizations of rare UBA1 variants in X-linked Spinal Muscular Atrophy.","date":"2017","source":"F1000Research","url":"https://pubmed.ncbi.nlm.nih.gov/29034082","citation_count":19,"is_preprint":false},{"pmid":"34193603","id":"PMC_34193603","title":"Zebrafish Uba1 Degrades IRF3 through K48-Linked Ubiquitination to Inhibit IFN Production.","date":"2021","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/34193603","citation_count":16,"is_preprint":false},{"pmid":"30249396","id":"PMC_30249396","title":"Administration of ubiquitin-activating enzyme UBA1 inhibitor PYR-41 attenuates angiotensin II-induced cardiac remodeling in mice.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30249396","citation_count":16,"is_preprint":false},{"pmid":"38091008","id":"PMC_38091008","title":"Sensitivity to targeted UBA1 inhibition in a myeloid cell line model of VEXAS syndrome.","date":"2023","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/38091008","citation_count":15,"is_preprint":false},{"pmid":"24805847","id":"PMC_24805847","title":"Characterization of ubiquitin-activating enzyme Uba1 in the nucleus by its mammalian temperature-sensitive mutant.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24805847","citation_count":15,"is_preprint":false},{"pmid":"39626673","id":"PMC_39626673","title":"UBA1 inhibition sensitizes cancer cells to PARP inhibitors.","date":"2024","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39626673","citation_count":14,"is_preprint":false},{"pmid":"30456359","id":"PMC_30456359","title":"Recruitment of ubiquitin-activating enzyme UBA1 to DNA by poly(ADP-ribose) promotes ATR signalling.","date":"2018","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/30456359","citation_count":14,"is_preprint":false},{"pmid":"25771124","id":"PMC_25771124","title":"A catechin-enriched green tea extract prevents glucose-induced survival reduction in Caenorhabditis elegans through sir-2.1 and uba-1 dependent hormesis.","date":"2015","source":"Fitoterapia","url":"https://pubmed.ncbi.nlm.nih.gov/25771124","citation_count":14,"is_preprint":false},{"pmid":"26028276","id":"PMC_26028276","title":"X-linked spinal muscular atrophy (SMAX2) caused by de novo c.1731C>T substitution in the UBA1 gene.","date":"2015","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/26028276","citation_count":13,"is_preprint":false},{"pmid":"39347709","id":"PMC_39347709","title":"UBA1 dysfunction in VEXAS and cancer.","date":"2024","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/39347709","citation_count":12,"is_preprint":false},{"pmid":"37344798","id":"PMC_37344798","title":"CircItgb5 promotes synthetic phenotype of pulmonary artery smooth muscle cells via interacting with miR-96-5p and Uba1 in monocrotaline-induced pulmonary arterial hypertension.","date":"2023","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/37344798","citation_count":12,"is_preprint":false},{"pmid":"32258175","id":"PMC_32258175","title":"Inhibition of the Ubiquitin-Activating Enzyme UBA1 Suppresses Diet-Induced Atherosclerosis in Apolipoprotein E-Knockout Mice.","date":"2020","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/32258175","citation_count":11,"is_preprint":false},{"pmid":"36038944","id":"PMC_36038944","title":"Exome sequencing can misread high variant allele fraction of somatic variants in UBA1 as hemizygous in VEXAS syndrome: a case report.","date":"2022","source":"BMC rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/36038944","citation_count":11,"is_preprint":false},{"pmid":"39806534","id":"PMC_39806534","title":"Hypomethylating agents for patients with VEXAS without myelodysplastic syndrome: Clinical outcome and longitudinal follow-up of vacuolization and UBA1 clonal dynamics.","date":"2025","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/39806534","citation_count":10,"is_preprint":false},{"pmid":"39533868","id":"PMC_39533868","title":"Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndrome.","date":"2024","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/39533868","citation_count":9,"is_preprint":false},{"pmid":"38167209","id":"PMC_38167209","title":"Dynamic monitoring of UBA1 somatic mutations in patients with relapsing polychondritis.","date":"2024","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/38167209","citation_count":8,"is_preprint":false},{"pmid":"35090310","id":"PMC_35090310","title":"ABCB1 limits the cytotoxic activity of TAK-243, an inhibitor of the ubiquitin-activating enzyme UBA1.","date":"2022","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/35090310","citation_count":8,"is_preprint":false},{"pmid":"32181232","id":"PMC_32181232","title":"A Pathogenic Missense Variant (c.1617G>A, p.Met539Ile) in UBA1 Causing Infantile X-Linked Spinal Muscular Atrophy (SMAX2).","date":"2020","source":"Frontiers in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/32181232","citation_count":6,"is_preprint":false},{"pmid":"31932168","id":"PMC_31932168","title":"X-linked infantile spinal muscular atrophy (SMAX2) caused by novel c.1681G>A substitution in the UBA1 gene, expanding the phenotype.","date":"2019","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/31932168","citation_count":6,"is_preprint":false},{"pmid":"38552317","id":"PMC_38552317","title":"Description of a novel splice site variant in UBA1 gene causing VEXAS syndrome.","date":"2024","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/38552317","citation_count":5,"is_preprint":false},{"pmid":"37108544","id":"PMC_37108544","title":"Novel Isoform DTX3c Associates with UBE2N-UBA1 and Cdc48/p97 as Part of the EphB4 Degradation Complex Regulated by the Autocrine IGF-II/IRA Signal in Malignant Mesothelioma.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37108544","citation_count":5,"is_preprint":false},{"pmid":"40906528","id":"PMC_40906528","title":"UBA1-depleted neutrophils disrupt immune homeostasis and induce VEXAS-like autoinflammatory disease in mice.","date":"2025","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/40906528","citation_count":4,"is_preprint":false},{"pmid":"26059705","id":"PMC_26059705","title":"Nuclear localization of ubiquitin-activating enzyme Uba1 is characterized in its mammalian temperature-sensitive mutant.","date":"2015","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/26059705","citation_count":4,"is_preprint":false},{"pmid":"36142209","id":"PMC_36142209","title":"Uba1: A Potential Ubiquitin-like Activator Protein of Urm1 in Toxoplasma gondii.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36142209","citation_count":4,"is_preprint":false},{"pmid":"35423322","id":"PMC_35423322","title":"Mode of inhibitory binding of epigallocatechin gallate to the ubiquitin-activating enzyme Uba1 via accelerated molecular dynamics.","date":"2021","source":"RSC advances","url":"https://pubmed.ncbi.nlm.nih.gov/35423322","citation_count":4,"is_preprint":false},{"pmid":"35707597","id":"PMC_35707597","title":"X-Linked Spinal Muscular Atrophy 2 due to a Synonymous Variant in the UBA1 Gene in a Family with Novel Findings from Turkey.","date":"2022","source":"Molecular syndromology","url":"https://pubmed.ncbi.nlm.nih.gov/35707597","citation_count":4,"is_preprint":false},{"pmid":"40858805","id":"PMC_40858805","title":"SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms.","date":"2025","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/40858805","citation_count":3,"is_preprint":false},{"pmid":"41068485","id":"PMC_41068485","title":"Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations.","date":"2025","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/41068485","citation_count":3,"is_preprint":false},{"pmid":"37873213","id":"PMC_37873213","title":"Shared and Distinct Mechanisms of UBA1 Inactivation Across Different Diseases.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/37873213","citation_count":3,"is_preprint":false},{"pmid":"35996994","id":"PMC_35996994","title":"Identification of UBA1 as the causative gene of an X-linked non-Kennedy spinal-bulbar muscular atrophy.","date":"2022","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35996994","citation_count":3,"is_preprint":false},{"pmid":"23022194","id":"PMC_23022194","title":"The functional role of UBA1 cysteine-278 in ubiquitination.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23022194","citation_count":3,"is_preprint":false},{"pmid":"37815921","id":"PMC_37815921","title":"High-Accuracy Prediction of Stabilizing Surface Mutations to the Three-Helix Bundle, UBA(1), with EmCAST.","date":"2023","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/37815921","citation_count":3,"is_preprint":false},{"pmid":"35430812","id":"PMC_35430812","title":"Residual Structure in the Denatured State of the Fast-Folding UBA(1) Domain from the Human DNA Excision Repair Protein HHR23A.","date":"2022","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35430812","citation_count":3,"is_preprint":false},{"pmid":"40239805","id":"PMC_40239805","title":"Rapid Screening and Monitoring of UBA1 Mutations in VEXAS Syndrome.","date":"2025","source":"The Journal of molecular diagnostics : JMD","url":"https://pubmed.ncbi.nlm.nih.gov/40239805","citation_count":2,"is_preprint":false},{"pmid":"36959858","id":"PMC_36959858","title":"UBA1 inhibition contributes radiosensitization of glioblastoma cells via blocking DNA damage repair.","date":"2023","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36959858","citation_count":2,"is_preprint":false},{"pmid":"25834782","id":"PMC_25834782","title":"Analysis of a temperature-sensitive mutation in Uba1: Effects of the click reaction on subsequent immunolabeling of proteins involved in DNA replication.","date":"2015","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/25834782","citation_count":2,"is_preprint":false},{"pmid":"40588566","id":"PMC_40588566","title":"Characterization of E1 enzyme dependencies in mutant-UBA1 human cells reveals UBA6 as a novel therapeutic target in VEXAS syndrome.","date":"2025","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/40588566","citation_count":1,"is_preprint":false},{"pmid":"40976851","id":"PMC_40976851","title":"Clinical Manifestations of VEXAS Syndrome Across a Broad Spectrum of UBA1 Mutation Burden.","date":"2025","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/40976851","citation_count":1,"is_preprint":false},{"pmid":"39762237","id":"PMC_39762237","title":"A novel UBA1 gene mutation in a patient with infantile respiratory distress syndrome.","date":"2025","source":"Human genome variation","url":"https://pubmed.ncbi.nlm.nih.gov/39762237","citation_count":1,"is_preprint":false},{"pmid":"40418703","id":"PMC_40418703","title":"Rapid clinical deployment of UBA1 testing in patients with VEXAS syndrome.","date":"2025","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/40418703","citation_count":1,"is_preprint":false},{"pmid":"41205381","id":"PMC_41205381","title":"Macrophage-specific UBA1 knockout attenuates sepsis-induced liver dysfunction by regulating inflammatory responses via the BMAL1/CLOCK-REV-ERBα axis.","date":"2025","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41205381","citation_count":1,"is_preprint":false},{"pmid":"38715663","id":"PMC_38715663","title":"A novel XNA-based Luminex assay to detect UBA1 somatic mutations associated with VEXAS syndrome.","date":"2024","source":"Practical laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38715663","citation_count":1,"is_preprint":false},{"pmid":"41765888","id":"PMC_41765888","title":"UBA1 promotes cardiac hypertrophy by suppressing autophagy via targeting ATG5 for ubiquitination.","date":"2026","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/41765888","citation_count":0,"is_preprint":false},{"pmid":"38405903","id":"PMC_38405903","title":"UBA1-CDK16 : A Sex-Specific Chimeric RNA and Its Role in Immune Sexual Dimorphism.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38405903","citation_count":0,"is_preprint":false},{"pmid":"37445840","id":"PMC_37445840","title":"Involvement in Fertilization and Expression of Gamete Ubiquitin-Activating Enzymes UBA1 and UBA6 in the Ascidian Halocynthia roretzi.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37445840","citation_count":0,"is_preprint":false},{"pmid":"41203132","id":"PMC_41203132","title":"A modular Uba1-nanobody fusion enables selective ubiquitin transfer to tagged E2 enzymes.","date":"2025","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/41203132","citation_count":0,"is_preprint":false},{"pmid":"42251322","id":"PMC_42251322","title":"UBA1 drives cell cycle to promote malignancy and serves as a therapeutic target in Ewing Sarcoma.","date":"2026","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/42251322","citation_count":0,"is_preprint":false},{"pmid":"40869363","id":"PMC_40869363","title":"Vacuolated Marrow Cytopenias from Copper Deficiency to UBA1-Mutant VEXAS: Molecular Landscape, Systematic Review, and Cost-Efficient Diagnostic Algorithm.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40869363","citation_count":0,"is_preprint":false},{"pmid":"42213831","id":"PMC_42213831","title":"UBA1-CDK16: A female-specific chimeric RNA emerging through evolution and involved in immune regulation.","date":"2026","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/42213831","citation_count":0,"is_preprint":false},{"pmid":"41287186","id":"PMC_41287186","title":"Targeting the E1 ubiquitin-activating enzyme Uba1 impairs male fertility in Bactrocera dorsalis.","date":"2025","source":"Pest management science","url":"https://pubmed.ncbi.nlm.nih.gov/41287186","citation_count":0,"is_preprint":false},{"pmid":"41882537","id":"PMC_41882537","title":"CDH4/UBA1/RBMX axis promotes polycystic ovary syndrome progression through YAP1 activation.","date":"2026","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/41882537","citation_count":0,"is_preprint":false},{"pmid":"42107927","id":"PMC_42107927","title":"Assessing the Frequency of VEXAS-Related Canonical UBA1 Mutations in Myelodysplastic Syndrome Patients.","date":"2026","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/42107927","citation_count":0,"is_preprint":false},{"pmid":"41482697","id":"PMC_41482697","title":"A Case of VEXAS Syndrome Initially Masked as Myelodysplastic Syndrome: Importance of Marrow Vacuolization and UBA1 Testing: A Case Report.","date":"2026","source":"The American journal of case reports","url":"https://pubmed.ncbi.nlm.nih.gov/41482697","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.06.680650","title":"UBA1 Mutations Drive RIPK1-Mediated Cell Death and Monocyte Dysfunction in VEXAS Syndrome","date":"2025-10-06","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.06.680650","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.09.648068","title":"Disturbing immune homeostasis by neutrophil loss of Uba1 induces VEXAS-like autoinflammatory disease in mice","date":"2025-04-15","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.09.648068","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.10.15.682570","title":"Ubiquitination regulates granulostasis and DRiP accumulation in SGs under heat stress via the E3 ligase MKRN2","date":"2025-10-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.15.682570","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.22.653244","title":"Primary CD34  <sup>+</sup>  cells of patients with VEXAS syndrome are highly sensitive to targeted treatment with TAK-243 and pevonedistat","date":"2025-05-24","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.22.653244","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.02.623560","title":"VEXAS anemia is a mosaic erythroblastopenia","date":"2024-12-04","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.02.623560","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.06.663376","title":"Fubylation as a Druggable Ubiquitin-Like Conjugation System Controlling Hippo Pathway Activity","date":"2025-07-06","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.06.663376","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.28.610114","title":"<i>SF3B1</i>  -mutant mis-splicing of  <i>UBA1</i>  confers a targetable therapeutic vulnerability through UBA1 inhibition","date":"2024-08-28","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.28.610114","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.25.620379","title":"Identification and characterization of UBA5 inhibitors","date":"2024-10-26","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.25.620379","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53131,"output_tokens":7436,"usd":0.135466,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16837,"output_tokens":7489,"usd":0.135705,"stage2_stop_reason":"end_turn"},"total_usd":0.271171,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2020,\n      \"finding\": \"Somatic mutations at p.Met41 in UBA1 result in loss of the canonical cytoplasmic isoform of UBA1 (UBA1b) and expression of a novel, catalytically impaired isoform initiated at p.Met67. Mutant peripheral-blood cells showed decreased ubiquitylation and activated innate immune pathways. Knockout of the cytoplasmic UBA1 isoform homologue in zebrafish caused systemic inflammation.\",\n      \"method\": \"Immunoblotting, flow cytometry, transcriptome and cytokine profiling, CRISPR-Cas9 zebrafish knockout\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (immunoblotting, flow cytometry, in vivo CRISPR model), independently replicated across subsequent studies\",\n      \"pmids\": [\"33108101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The p.Met41Val variant supports less UBA1b (cytoplasmic isoform) translation than p.Met41Leu or p.Met41Thr, as shown by in vitro reporter assays. Residual UBA1b translation level is fundamental to VEXAS pathogenesis and prognosis. A second mutation (p.Gly40Ala) in cis rescued UBA1b translation levels reduced by p.Met41Leu.\",\n      \"method\": \"In vitro reporter translation assay, patient-derived cell analysis, multivariate survival analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct in vitro reporter assay with mutagenesis, replicated across multiple patient genotypes and patient-derived cells\",\n      \"pmids\": [\"35793467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"p.Met41 VEXAS mutations alter cytoplasmic isoform expression, whereas non-p.Met41 VEXAS mutations reduce catalytic activity of nuclear and cytoplasmic isoforms by diverse mechanisms including aberrant oxyester formation. Non-p.Met41 mutations most prominently impair transthioesterification (ubiquitin transfer to cytoplasmic E2 enzymes). SMA-causing UBA1 mutations instead render UBA1 thermolabile rather than blocking E2 charging.\",\n      \"method\": \"In vitro enzymatic assays (ubiquitin thioester formation, transthioesterification, oxyester detection), mutagenesis, patient-derived cell analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple in vitro biochemical assays with mutagenesis across diverse disease-causing variants, replicated in preprint (PMID 37873213)\",\n      \"pmids\": [\"38360993\", \"37873213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"UBA1 is required for ubiquitin conjugate formation at DNA double-strand break sites. siRNA knockdown of UBA1 (but not UBA6) impaired formation of ubiquitin conjugates at DNA damage sites and prevented IR-induced foci (IRIF) by 53BP1 and BRCA1. Chemical inhibition of UBA1 prevented IRIF formation and severely impaired DSB repair. Upstream steps (H2AX phosphorylation, MDC1 recruitment) were unaffected.\",\n      \"method\": \"siRNA knockdown, chemical inhibition, immunofluorescence for IRIF, comet assay for DSB repair\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic (siRNA) and pharmacological inhibition with multiple orthogonal readouts; negative result for UBA6 specificity controls\",\n      \"pmids\": [\"22456334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TAK-243 preferentially binds UBA1 over related E1 enzymes UBA2, UBA3, and UBA6 in intact AML cells. Missense mutations in the adenylation domain of UBA1 confer resistance to TAK-243, identifying the adenylation domain as the inhibitor binding site.\",\n      \"method\": \"Activity-based protein profiling in intact cells, selection of drug-resistant cell populations with missense mutation identification\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct target engagement assay in cells, resistance mutations confirm on-target mechanism\",\n      \"pmids\": [\"29884901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structure of S. pombe Uba1 in complex with Ubc15 reveals a distinct E2 binding mode that substantially alters the interaction network at the E1-E2 interface compared to previously solved E1-E2 structures. The intrinsically low E2 activity of Ubc15 results from an acidic residue at its N-terminal region. Phosphorylation of serine/threonine-rich N termini of other Ub E2s was demonstrated biochemically and in cells to serve as a negative regulatory mechanism of E2 activity.\",\n      \"method\": \"X-ray crystallography, structure-function mutagenesis, biochemical E2 charging assays, cell-based phosphorylation assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus functional mutagenesis and orthogonal biochemical and cell-based validation\",\n      \"pmids\": [\"28162934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Auranofin binds to UBA1's ubiquitin fold domain and conjugates to Cys1039, enhancing UBA1 interactions with at least 20 different E2 ubiquitin-conjugating enzymes and facilitating ubiquitin charging to E2. This increases activities of seven representative E3s in vitro and promotes ubiquitination and degradation of misfolded ER proteins during ER-associated degradation and outer mitochondrial membrane-associated degradation.\",\n      \"method\": \"Biochemical binding assay, covalent modification mapping (Cys1039), in vitro E2 charging assay, E3 activity assay, cellular ERAD assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal in vitro assays plus cell-based validation, with identification of binding site by mutagenesis\",\n      \"pmids\": [\"37558718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"UBA1 is recruited to DNA by poly(ADP-ribose) (PAR), and this PAR-mediated association is necessary for ATR-dependent phosphorylation of RPA and CHK1 in response to DNA damage. UBA1 interacts directly with PAR via a solvent-accessible, positively charged patch conserved in Animalia but not Fungi.\",\n      \"method\": \"Human cell-free system, PAR interaction assay, direct UBA1-PAR binding assay, ATR signaling readout (RPA/CHK1 phosphorylation)\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — reconstituted cell-free system, direct binding demonstrated, functional consequence (ATR signaling) measured, conservation analysis supports mechanism\",\n      \"pmids\": [\"30456359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"UBA1 levels are reduced in mouse and zebrafish SMA models and in patient iPSC-derived motor neurons. Systemic AAV9-mediated restoration of UBA1 in SMA mice ameliorated weight loss, increased survival and motor performance, and improved neuromuscular pathology, reversing widespread ubiquitin homeostasis perturbations.\",\n      \"method\": \"AAV9 gene therapy in SMA mice, zebrafish rescue experiments, iPSC motor neuron derivation, ubiquitin conjugate measurement\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo rescue in two model organisms with multiple functional readouts, replicated mechanistic link between SMN loss and UBA1 reduction\",\n      \"pmids\": [\"27699224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Restoration of UBA1 was sufficient to correct sensory-motor connectivity defects in SMA mice. Aminoacyl-tRNA synthetase GARS was identified as a downstream target of UBA1, regulated by a non-canonical pathway independent of ubiquitylation. Dysregulation of UBA1/GARS disrupted sensory neuron fate, phenocopying GARS-dependent Charcot-Marie-Tooth defects.\",\n      \"method\": \"AAV9-UBA1 rescue in SMA mice, proteomics (GARS identification as UBA1 target), sensory-motor connectivity electrophysiology, genetic epistasis\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo rescue, proteomics-based substrate identification, epistasis with GARS, multiple orthogonal functional readouts\",\n      \"pmids\": [\"30239612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Uba1 (the E1 ubiquitin-activating enzyme) is required for an Atg7- and Atg3-independent autophagy pathway in Drosophila intestinal cells during programmed cell size reduction. Loss of Uba1 function blocks autophagy and cell shrinkage, revealing a role for ubiquitin activation in autophagy distinct from canonical Atg8 conjugation.\",\n      \"method\": \"Genetic loss-of-function in Drosophila, autophagy and cell size assays, epistasis with Atg7/Atg3/Atg8\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in Drosophila with clear functional readout, contrasted with Atg7/Atg3 null controls\",\n      \"pmids\": [\"23873149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In Drosophila, weak Uba1 alleles protect cells from apoptosis while strong alleles cause apoptosis and cell cycle arrest with failure to degrade cyclins. Strong Uba1 mutant clones non-autonomously stimulate neighboring wild-type tissue to proliferate by failing to downregulate Notch signaling.\",\n      \"method\": \"Drosophila genetic mosaic analysis, clonal analysis, cyclin immunostaining, Notch pathway epistasis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Drosophila mosaic genetics with multiple alleles, mechanistic link to Notch signaling and cyclin degradation demonstrated\",\n      \"pmids\": [\"18045837\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Acetylation of ubiquitin at K11, K27, K33, K48, or K63 alters the turnover number for E2~Ub conjugate formation by the E1 enzyme Uba1, as shown by FRET-based kinetic assays. Acetylation at specific Ub lysines modulates catalytic efficiency of the UBA1-mediated E2 charging step.\",\n      \"method\": \"In vitro synthesis of acetylated ubiquitin variants, FRET-based kinetic E2 charging assay (CyPet-Ub/YPet-E2)\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with synthetic substrates and kinetic measurements, single lab but rigorous\",\n      \"pmids\": [\"33848125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"A novel UBA1 variant p.Gly477Ala leads to both decreased E1 ubiquitin thioester formation and decreased E2 enzyme charging, demonstrated by in vitro enzymatic assays, expanding the catalog of catalytic loss-of-function mechanisms in VEXAS.\",\n      \"method\": \"In vitro ubiquitin thioester formation assay, E2 charging assay\",\n      \"journal\": \"Arthritis & rheumatology (Hoboken, N.J.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro enzymatic assay, single lab, single variant\",\n      \"pmids\": [\"36762418\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In vitro enzymatic assay of a novel UBA1 variant p.Ser621Cys demonstrated a catalytic defect, supporting pathogenicity in VEXAS syndrome.\",\n      \"method\": \"In vitro enzymatic assay\",\n      \"journal\": \"JAMA\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — single in vitro assay, single variant, single lab\",\n      \"pmids\": [\"36692560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Of three known XL-SMA missense variants in the adenylation domain (Exon 15) of UBA1, only one impairs ubiquitin-adenylating (adenylation) activity in vitro, while all three retain normal ubiquitin thioester formation and transthioesterification rates equal to wild-type.\",\n      \"method\": \"In vitro Uba1 adenylation assay, thioester formation assay, transthioesterification assay\",\n      \"journal\": \"F1000Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct in vitro enzymatic characterization of three variants, single lab, limited mechanistic follow-up\",\n      \"pmids\": [\"29034082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A Met256Ile point mutation in Uba1 (tsTM3 cells) causes loss of nuclear UBA1 at non-permissive temperature, impairs ubiquitin system function in the nucleus, leads to accumulation of geminin and Cdt1 (DNA replication licensing factors), and causes S-to-G2 cell cycle arrest. Nuclear localization of UBA1 is required to rescue these defects.\",\n      \"method\": \"Temperature-sensitive CHO mutant complementation, GFP-Uba1 localization, fluorescent cell cycle indicator, Western blot for geminin/Cdt1\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — temperature-sensitive mutant with complementation, localization and functional readouts, single lab\",\n      \"pmids\": [\"24805847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Cys278 of UBA1 affects ubiquitin charging through conformational changes rather than direct participation at the UBA1-ubiquitin interface; UBA1(C278S) mutant forms a thioester on Cys632 (canonical catalytic cysteine) but ubiquitin conjugates persist longer compared to wild-type, indicating impaired downstream transfer.\",\n      \"method\": \"Site-directed mutagenesis (C278S, C632S), ubiquitin thioester assay, transfection of HEK293T and CMT93 cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Weak — mutagenesis with in vitro/cell-based assay, single lab, single study\",\n      \"pmids\": [\"23022194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"UBA1 localizes to the acrosomal caps of spermatids and is enzymatically active in isolated sperm acrosomes (confirmed by thiol ester assay with biotinylated ubiquitin). Pharmacological inhibition of UBA1 with PYR-41 during sperm capacitation alters outer acrosomal membrane remodeling, impairs capacitation-induced protein modifications, and significantly reduces in vitro fertilization rates.\",\n      \"method\": \"Western blotting, immunofluorescence, thiol ester assay on isolated acrosomes, flow cytometry (FITC-PNA), in vitro fertilization with PYR-41 inhibitor\",\n      \"journal\": \"International journal of andrology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — enzymatic activity confirmed in isolated organelles plus pharmacological inhibition with functional readout, single lab\",\n      \"pmids\": [\"21950462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Temperature-sensitive mutation in C. elegans uba-1 (the sole E1 enzyme) substantially reduces ubiquitin conjugate levels and causes meiotic progression delays in early embryos, synthetic lethality with anaphase-promoting complex (APC/C) alleles, and defects in sperm fertility, body size control, and sex-specific development.\",\n      \"method\": \"C. elegans temperature-sensitive genetics, ubiquitin conjugate immunoblot, genetic epistasis with APC/C mutants\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple developmental phenotypes with epistasis to APC/C, biochemical confirmation of reduced conjugates, replicated across developmental stages\",\n      \"pmids\": [\"18636104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"UBA1M41V-mutated monocytes exhibit TNF-α-induced cell death characterized by RIPK1 phosphorylation and MLKL/caspase-8-mediated death, associated with defective NF-κB transcriptional induction and reduced cFLIP(L). UBA1-mutated macrophages display an inflammatory transcriptional profile with increased chemokine secretion and defective efferocytosis due to lysosomal dysfunction.\",\n      \"method\": \"CRISPR-engineered THP-1 monocytic cell model (UBA1 M41V), ex vivo patient samples, RIPK1 phosphorylation assay, MLKL/caspase-8 activation assays, NF-κB reporter, efferocytosis assay\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — engineered human cell model plus patient-derived samples, multiple mechanistic readouts, preprint not yet peer reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.10.06.680650\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Neutrophil-specific Uba1 depletion (to ~30% residual Uba1) in mice induces VEXAS-like autoinflammatory symptoms including increased neutrophil counts, elevated proinflammatory cytokines (IL-1β, IL-6, TNFα), myeloid vacuoles, and dermatitis. Loss of Uba1 in HSCs, B cells, T cells, or megakaryocytes does not produce autoinflammatory disease, identifying neutrophils as a key pathogenic cell type.\",\n      \"method\": \"Nine Cre/flox conditional knockout mouse models, flow cytometry, cytokine measurement, histology\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic comparison of nine cell-type-specific CKO models, clear epistasis, in vivo functional readout, published peer-reviewed\",\n      \"pmids\": [\"40906528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"UBA1M41V mutant cells exhibit acquired dependency on UBA6 (a paralogous E1 enzyme) that compensates for UBA1 dysfunction. TAK-243 preferentially inhibits UBA6 activity over UBA1 at relevant concentrations. Genetic or pharmacological inhibition of UBA6 selectively impairs growth and colony formation of UBA1M41V cells while sparing wild-type cells.\",\n      \"method\": \"CRISPR-engineered THP1 UBA1M41V model, proteomic analysis, shRNA knockdown, phytic acid (UBA6-specific inhibitor), competition colony formation assay\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — engineered human cell model, multiple genetic and pharmacological approaches, single lab\",\n      \"pmids\": [\"40588566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"UBA1 directly interacts with ATG5 and promotes its ubiquitination and proteasomal degradation, leading to autophagy suppression. Cardiomyocyte-specific UBA1 knockdown protects against TAC-induced hypertrophy by preserving ATG5-mediated autophagy; ATG5 deletion abrogates this protection.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, rAAV9-mediated knockdown/overexpression in mice, TAC model, ATG5 epistasis by deletion\",\n      \"journal\": \"Cell communication and signaling : CCS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus in vivo genetic epistasis, multiple readouts, single lab, newly published\",\n      \"pmids\": [\"41765888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"UBA1 interacts with BMAL1 and increases its ubiquitination and proteasomal degradation in macrophages, reducing REV-ERBα transcriptional activity and increasing proinflammatory cytokine production, thereby exacerbating sepsis-associated liver dysfunction.\",\n      \"method\": \"Macrophage-specific UBA1 knockout mice, co-immunoprecipitation, ubiquitination assay, CLP sepsis model, liver function and cytokine measurements\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, in vivo KO model, mechanistic pathway identification, single lab\",\n      \"pmids\": [\"41205381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In VEXAS, UBA1-mutated hematopoietic stem and progenitor cells (HSPCs) are biased toward myeloid (granulocytic) differentiation and away from lymphoid differentiation. Activation of interferon and TNF-α inflammatory pathways occurs in primitive hematopoietic cells and particularly in the myeloid lineage, with inflammation intrinsic to UBA1-mutated HSCs.\",\n      \"method\": \"Single-cell transcriptome sequencing of bone marrow mononuclear cells and HSPCs from VEXAS patients\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single-cell transcriptomics across multiple patients, but transcriptomic rather than direct mechanistic experiment\",\n      \"pmids\": [\"37586319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"AZGP1P2 binds to UBA1 and RBM15; UBA1 promotes ubiquitin-dependent degradation of RBM15 via ubiquitination. This was shown by RNA pull-down with mass spectrometry, co-immunoprecipitation, and RNA immunoprecipitation assays.\",\n      \"method\": \"RNA pull-down/mass spectrometry, co-immunoprecipitation, RNA immunoprecipitation, xenograft mouse model\",\n      \"journal\": \"Research (Washington, D.C.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP plus functional degradation readout, multiple methods, single lab\",\n      \"pmids\": [\"37854295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"UBA1 inhibition by TAK-243 impairs homologous recombination (HR) DNA repair and increases PARylation, sensitizing HR-proficient ovarian cancer cells to PARP inhibitors. A genome-wide CRISPR knockout screen identified UBA1 depletion as conferring sensitivity to PARPi.\",\n      \"method\": \"Genome-wide CRISPR KO screen, siRNA/pharmacological UBA1 inhibition, HR repair assay, PARylation assay, patient-derived xenograft in vivo combination study\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR screen discovery confirmed with orthogonal genetic and pharmacological methods, mechanistic HR assay, and in vivo validation\",\n      \"pmids\": [\"39626673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"A modular Uba1-nanobody (VHH05) fusion enzyme (Uba1-VHH05), in which the ubiquitin-fold domain (UFD) is replaced by a nanobody, selectively transfers ubiquitin to E2 enzymes fused to the cognate epitope tag, demonstrating that the UFD of Uba1 is the domain responsible for E2 selection and ubiquitin transfer specificity.\",\n      \"method\": \"Domain-swap protein engineering, in vitro ubiquitin transfer assay, Ub-Dha activity-based probe, polyubiquitin chain formation reconstitution\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct in vitro reconstitution with engineered enzyme, single lab, single study\",\n      \"pmids\": [\"41203132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SF3B1K700E mutation causes mis-splicing of UBA1 transcripts in hematopoietic cells, introducing protein instability and decreasing total UBA1 protein levels, thereby rendering SF3B1-mutated cells selectively vulnerable to UBA1 inhibitor TAK-243.\",\n      \"method\": \"Isogenic SF3B1K700E/WT iPSC lines differentiated into hematopoietic cells, full-length RNA sequencing, Western blot, TAK-243 colony-forming assay on primary CD34+ MDS cells\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — isogenic cell model, confirmed in primary patient CD34+ cells and MDS cohort RNA-seq, multiple orthogonal methods\",\n      \"pmids\": [\"40858805\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"UBA1 is the primary E1 ubiquitin-activating enzyme that initiates ubiquitin conjugation by adenylating ubiquitin and forming a high-energy thioester at its catalytic cysteine (Cys632), then transfers ubiquitin to tens of E2 conjugating enzymes via its C-terminal ubiquitin-fold domain; it exists as distinct nuclear and cytoplasmic isoforms (the cytoplasmic isoform, UBA1b, is translated from Met41), functions at DNA damage sites via poly(ADP-ribose)-mediated recruitment to support ATR signaling, regulates autophagy and cell cycle progression, and controls specific substrate ubiquitination events including BMAL1 and ATG5 degradation; somatic loss-of-function mutations at Met41 specifically abrogate cytoplasmic UBA1b expression, reducing E2 charging and causing the VEXAS inflammatory-hematologic syndrome, while other disease-causing mutations impair transthioesterification or render the enzyme thermolabile through distinct mechanisms.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"UBA1 is the principal E1 ubiquitin-activating enzyme that initiates the ubiquitin conjugation cascade by adenylating ubiquitin, forming a high-energy thioester at its catalytic cysteine (Cys632), and charging ubiquitin onto downstream E2 conjugating enzymes [#2, #17]. Its C-terminal ubiquitin-fold domain (UFD) is the determinant of E2 selection and transfer specificity: replacing the UFD with a nanobody redirects ubiquitin transfer exclusively to epitope-tagged E2s [#28]. Charging activity is tunable through multiple inputs — acetylation of distinct ubiquitin lysines alters E2~Ub turnover [#12], covalent modification of the UFD at Cys1039 by auranofin enhances E2 engagement across more than twenty E2 enzymes [#6], and E2 N-terminal phosphorylation acts as a negative regulator at the E1-E2 interface [#5]. UBA1 exists as nuclear and cytoplasmic isoforms; the cytoplasmic isoform (UBA1b) is translated from Met41, and its nuclear pool is required to maintain ubiquitin-dependent turnover of replication-licensing factors and orderly S-to-G2 progression [#0, #16]. The enzyme acts at DNA double-strand breaks, where poly(ADP-ribose) recruits UBA1 to support ubiquitin-conjugate formation, 53BP1/BRCA1 focus assembly, and ATR-dependent phosphorylation of RPA and CHK1 [#3, #7]. Beyond bulk conjugation, UBA1 controls specific substrate-degradation events, directly ubiquitinating ATG5 to suppress autophagy [#23] and BMAL1 to dampen REV-ERBα activity and amplify inflammatory cytokine output [#24], and it participates in a non-canonical autophagy pathway and APC/C-coupled cyclin degradation conserved across model organisms [#10, #11, #19]. Somatic Met41 mutations selectively abrogate UBA1b, reducing E2 charging and causing the inflammatory-hematologic VEXAS syndrome, whereas germline mutations cause spinal muscular atrophy by rendering the enzyme thermolabile; non-Met41 disease variants instead impair transthioesterification or catalytic activity through distinct mechanisms including aberrant oxyester formation [#0, #1, #2, #8]. UBA1 inhibition or loss is being leveraged therapeutically, with TAK-243-mediated E1 blockade impairing homologous recombination and sensitizing cancers to PARP inhibition [#27].\",\n  \"teleology\": [\n    {\n      \"year\": 2007,\n      \"claim\": \"Established that E1 ubiquitin activation gates cell-cycle progression and tissue homeostasis, not merely bulk protein turnover, by linking Uba1 loss to failed cyclin degradation and aberrant Notch signaling.\",\n      \"evidence\": \"Drosophila mosaic clonal genetics with multiple alleles, cyclin immunostaining and Notch epistasis\",\n      \"pmids\": [\"18045837\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not identify which E3/E2 routes the cyclin and Notch ubiquitination\", \"Phenotypes are organismal, leaving the direct substrate set undefined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed the sole organismal E1 is required across meiosis, fertility, and development and operates upstream of the APC/C, defining the breadth of processes dependent on ubiquitin activation.\",\n      \"evidence\": \"C. elegans temperature-sensitive uba-1 genetics, ubiquitin-conjugate immunoblot, epistasis with APC/C mutants\",\n      \"pmids\": [\"18636104\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not resolve substrate-level mechanisms for individual phenotypes\", \"Genetic, not biochemical, link to APC/C\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified UBA1 as the specific E1 that drives ubiquitin-conjugate formation at DNA double-strand breaks, placing ubiquitin activation downstream of damage sensing but upstream of repair-factor recruitment.\",\n      \"evidence\": \"siRNA knockdown and chemical inhibition with IRIF imaging and comet repair assay, UBA6 negative controls\",\n      \"pmids\": [\"22456334\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not identify the recruiting signal or relevant E2/E3 at breaks\", \"Does not define which repair-pathway substrates require UBA1\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Refined the catalytic mechanism by showing Cys278 influences ubiquitin charging through conformational change rather than direct chemistry, distinguishing the canonical catalytic Cys632 from allosteric cysteines.\",\n      \"evidence\": \"Site-directed mutagenesis (C278S, C632S), thioester assays in HEK293T and CMT93 cells\",\n      \"pmids\": [\"23022194\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, no structural confirmation of the proposed conformational change\", \"Downstream transfer defect inferred from conjugate persistence rather than direct kinetics\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed a ubiquitin-activation requirement for a non-canonical autophagy pathway independent of the Atg7/Atg3 conjugation machinery, broadening UBA1's role in degradative cell biology.\",\n      \"evidence\": \"Drosophila loss-of-function with autophagy/cell-size assays and Atg7/Atg3/Atg8 epistasis\",\n      \"pmids\": [\"23873149\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not define the ubiquitin substrates that drive this autophagy route\", \"Mechanism of Atg-independence unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated that nuclear UBA1 localization is specifically required to maintain ubiquitin-dependent turnover of replication-licensing factors and prevent S/G2 arrest, separating nuclear from cytoplasmic enzyme function.\",\n      \"evidence\": \"Temperature-sensitive CHO mutant (Met256Ile) complementation, GFP-Uba1 imaging, geminin/Cdt1 immunoblot\",\n      \"pmids\": [\"24805847\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, single mutant\", \"Mechanism of UBA1 nuclear import not addressed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Connected UBA1 reduction causally to spinal muscular atrophy pathology by showing AAV9-delivered UBA1 restores survival, motor function, and ubiquitin homeostasis in vivo.\",\n      \"evidence\": \"AAV9 gene therapy in SMA mice, zebrafish rescue, iPSC motor neurons, ubiquitin-conjugate measurement\",\n      \"pmids\": [\"27699224\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not identify the disease-relevant substrates downstream of UBA1 loss\", \"Does not explain how SMN loss reduces UBA1\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Provided structural and biochemical definition of the E1-E2 interface and showed E2 N-terminal phosphorylation negatively regulates charging, identifying a post-translational control layer on UBA1 output.\",\n      \"evidence\": \"X-ray crystallography of S. pombe Uba1-Ubc15, structure-function mutagenesis, biochemical and cell-based phosphorylation assays\",\n      \"pmids\": [\"28162934\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure from fission yeast ortholog\", \"Generality of phospho-regulation across human E2s not exhaustively mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed XL-SMA adenylation-domain variants mostly retain thioester and transthioesterification activity, indicating SMA pathogenicity is not simply a charging block and pointing toward subtler defects.\",\n      \"evidence\": \"In vitro adenylation, thioester, and transthioesterification assays on three variants\",\n      \"pmids\": [\"29034082\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, three variants only\", \"Does not establish the in vivo defect for the two variants with normal in vitro activity\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified poly(ADP-ribose) as the recruitment signal that brings UBA1 to damaged DNA and showed this association is required for ATR-dependent RPA/CHK1 phosphorylation, defining a mechanism for UBA1 action at breaks.\",\n      \"evidence\": \"Human cell-free system, direct UBA1-PAR binding assay, ATR signaling readouts, conservation analysis\",\n      \"pmids\": [\"30456359\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not identify ubiquitination substrates feeding ATR activation\", \"PAR-binding patch mapped by conservation rather than structure\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked UBA1 to neuronal connectivity and identified GARS as a downstream target regulated non-canonically and independent of ubiquitylation, expanding UBA1 function beyond conjugation chemistry.\",\n      \"evidence\": \"AAV9-UBA1 rescue in SMA mice, proteomics, sensory-motor electrophysiology, GARS epistasis\",\n      \"pmids\": [\"30239612\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular nature of the non-canonical UBA1-GARS regulation unresolved\", \"Generality beyond sensory neurons unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Validated UBA1 as the cellular target of TAK-243 and mapped the adenylation domain as the inhibitor binding site through resistance mutations, enabling pharmacological dissection and therapeutic targeting.\",\n      \"evidence\": \"Activity-based protein profiling in intact AML cells, selection of drug-resistant missense mutations\",\n      \"pmids\": [\"29884901\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity over UBA6 later shown to be concentration-dependent\", \"Does not define the substrate-level consequences of inhibition\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined the molecular basis of VEXAS by showing somatic Met41 mutations ablate cytoplasmic UBA1b, generate an impaired Met67-initiated isoform, reduce ubiquitylation, and trigger innate immune activation.\",\n      \"evidence\": \"Immunoblotting, flow cytometry, transcriptome/cytokine profiling, CRISPR zebrafish knockout\",\n      \"pmids\": [\"33108101\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not establish which inflammatory substrates accumulate\", \"Cell-type origin of disease not pinpointed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Quantified ubiquitin acetylation as a regulator of UBA1 catalytic efficiency, showing site-specific lysine acetylation tunes E2~Ub turnover and adds a substrate-side control on the cascade.\",\n      \"evidence\": \"Synthetic acetylated ubiquitin variants and FRET-based kinetic E2-charging assay\",\n      \"pmids\": [\"33848125\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vitro only; physiological acetylation stoichiometry unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Localized VEXAS inflammation to the hematopoietic stem cell compartment, showing UBA1-mutant HSPCs are myeloid-biased and intrinsically activate interferon/TNF programs.\",\n      \"evidence\": \"Single-cell transcriptome sequencing of patient bone marrow and HSPCs\",\n      \"pmids\": [\"37586319\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcriptomic correlation rather than direct mechanism\", \"Does not identify the molecular trigger of lineage bias\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established that residual UBA1b translation level dictates VEXAS severity, with Met41 variants ranked by translational output and a cis Gly40Ala mutation able to rescue UBA1b.\",\n      \"evidence\": \"In vitro reporter translation assay, patient-derived cells, multivariate survival analysis\",\n      \"pmids\": [\"35793467\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not connect translation level to specific downstream substrate defects\", \"Reporter-based quantification of translation\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed UBA1 inhibition impairs homologous recombination and elevates PARylation, providing a mechanistic rationale for combining E1 blockade with PARP inhibition in cancer.\",\n      \"evidence\": \"Genome-wide CRISPR screen, genetic/pharmacological UBA1 inhibition, HR and PARylation assays, patient-derived xenograft\",\n      \"pmids\": [\"39626673\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"HR substrates requiring UBA1 not individually identified\", \"Relationship to the PAR-recruitment mechanism at breaks not directly tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Mapped a regulatory small molecule (auranofin) to the UFD at Cys1039 and showed UFD modification enhances E2 engagement and downstream E3 and ERAD/OMMAD activity, reinforcing the UFD as the E2-handoff module.\",\n      \"evidence\": \"Biochemical binding, Cys1039 mapping, E2-charging and E3-activity assays, cellular ERAD assay\",\n      \"pmids\": [\"37558718\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological ligand of this UFD site unknown\", \"Whether endogenous modification regulates UBA1 in cells untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Resolved the distinct biochemical lesions across UBA1 disease variants, showing Met41 mutations alter isoform expression while non-Met41 mutations impair catalysis (including aberrant oxyester formation) and SMA mutations confer thermolability.\",\n      \"evidence\": \"In vitro thioester, transthioesterification, and oxyester assays with mutagenesis and patient cells\",\n      \"pmids\": [\"38360993\", \"37873213\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not link each biochemical defect to a clinical phenotype quantitatively\", \"In vitro assays may not capture cellular compensation\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified the UFD as the structural determinant of E2 selection by demonstrating that a UFD-to-nanobody swap redirects ubiquitin transfer to tagged E2 partners.\",\n      \"evidence\": \"Domain-swap protein engineering and in vitro ubiquitin-transfer and polyubiquitin reconstitution\",\n      \"pmids\": [\"41203132\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Engineered system; native UFD-E2 contact map not solved here\", \"Single lab/study\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Pinpointed neutrophils as the pathogenic cell type in VEXAS-like disease, showing partial Uba1 depletion in neutrophils—but not HSCs, lymphocytes, or megakaryocytes—reproduces autoinflammation.\",\n      \"evidence\": \"Nine Cre/flox conditional knockout mouse models with cytokine, flow, and histology readouts\",\n      \"pmids\": [\"40906528\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation with HSC-intrinsic inflammation reports unresolved\", \"Molecular trigger within neutrophils not defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined cell-death and inflammatory consequences of UBA1 dysfunction, linking Met41 mutation to TNF-driven RIPK1/MLKL/caspase-8 death, defective NF-κB induction, and impaired macrophage efferocytosis.\",\n      \"evidence\": \"CRISPR THP-1 UBA1 M41V model and patient samples, RIPK1/MLKL/caspase-8 and NF-κB and efferocytosis assays (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.10.06.680650\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Not yet peer reviewed\", \"Direct substrate causing NF-κB defect not identified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Revealed an acquired UBA6 dependency in UBA1-mutant cells, showing the paralogous E1 compensates and is selectively targetable, refining the pharmacology of E1 inhibition.\",\n      \"evidence\": \"CRISPR THP-1 UBA1 M41V model, proteomics, shRNA, phytic acid (UBA6 inhibitor), competition colony assays\",\n      \"pmids\": [\"40588566\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, engineered cell model\", \"Mechanism of UBA6 compensation not detailed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended UBA1's substrate repertoire to specific degradation targets driving disease, showing direct ubiquitination and proteasomal degradation of ATG5 (suppressing protective autophagy in cardiac hypertrophy), BMAL1 (amplifying inflammation in sepsis), and RBM15 in cancer.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, in vivo conditional knockdown/knockout with epistasis (ATG5/BMAL1/RBM15)\",\n      \"pmids\": [\"41765888\", \"41205381\", \"37854295\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Each substrate shown in a single lab/context\", \"The E2/E3 partners mediating these specific events not identified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connected splicing-factor mutations to UBA1 vulnerability, showing SF3B1K700E mis-splices UBA1 and lowers its level, sensitizing mutant hematopoietic cells to TAK-243.\",\n      \"evidence\": \"Isogenic SF3B1 iPSC-derived hematopoietic cells, full-length RNA-seq, Western blot, TAK-243 colony assay on primary CD34+ MDS cells\",\n      \"pmids\": [\"40858805\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not establish therapeutic window in patients\", \"Mechanism of selective vulnerability beyond UBA1 reduction not fully resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved which specific E2/E3 routes and substrate sets mediate UBA1's distinct functions at DNA breaks, in autophagy/cell cycle, and in inflammatory signaling, and how reduced cytoplasmic charging is mechanistically converted into the cell-type-specific inflammatory program of VEXAS.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified mechanism linking UBA1b loss to neutrophil-intrinsic inflammation\", \"Substrate-level changes upon partial E1 loss largely uncharacterized\", \"Reconciliation of HSC-intrinsic versus neutrophil-specific disease models pending\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [2, 17, 23, 24, 26]},\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [2, 5, 28]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [2, 4, 15]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [2, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [16]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2, 6]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [3, 7, 27]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [11, 16, 19]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [10, 23]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 20, 21, 24, 25]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 2, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"UBA6\", \"ATG5\", \"BMAL1\", \"RBM15\", \"GARS\", \"AZGP1P2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":8,"faith_pct":87.5}}